Friday, July 28, 2023
UltraSight announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology.
UltraSight's AI-powered ultrasound guidance technology appears to be a gamechanger in the field of cardiac imaging and patient care, promising better outcomes and improved access to cardiac monitoring for patients across various care settings. This software will assist medical professionals without sonography experience in acquiring cardiac ultrasound images, specifically the 10 standard views of the heart.
The UltraSight real-time AI guidance software can be used in various settings, allowing for easier access to cardiac monitoring and more widespread detection of heart disease. This advancement will enable hospital staff to make quicker clinical decisions with increased confidence, improving patient triage and treatment efficiency.
One of the significant challenges with traditional ultrasound has been its user-dependant functionality and subjectivity in image quality assessment. UltraSight's AI guidance addresses these hurdles, ensuring diagnostic efficiency and a better overall experience for both medical professionals and patients.
With this regulatory clearance, the solution can be more widely adopted and contribute to increasing patient adherence to crucial treatments for chronic heart disease.
